Wall Street Lunch: Lilly In Limelight [Seeking Alpha]
ResMed Inc. (RMD)
Last resmed inc. earnings: 4/30 04:05 pm
Check Earnings Report
US:NYSE Investor Relations:
investors.resmed.com/investor-relations/default.aspx
Company Research
Source: Seeking Alpha
Abbott posts Q1 results beat, Travelers earnings hurt by elevated catastrophe losses. Mortgage servicing within housing-finance will benefit from a higher-for-longer rate environment - Wedbush. Listen below or on the go on Apple Podcasts and Spotify Zepbound sees positive outcomes in Phase 3 clinical trials for sleep disorder. (0:16) Walmart teams up with Jessica Simpson. (3:25) Cathie Wood's flagship ARRK ETF f alls below key technical level. (3:42) This is an abridged transcript of the podcast. Our top story so far Eli Lilly ( NYSE: LLY ) announced that its weight loss therapy tirzepatide reached its main goals in two Phase 3 trials for patients with obesity and obstructive sleep apnea , a sleep-related breathing disorder. Citing topline data, Lilly said tirzepatide, marketed as Zepbound, significantly reduced the trials' primary endpoints compared to a placebo. Lilly's SURMOUNT-OSA program, which involved 469 adults with moderate-to-severe OSA and obesity across mu
Show less
Read more
Impact Snapshot
Event Time:
RMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RMD alerts
High impacting ResMed Inc. news events
Weekly update
A roundup of the hottest topics
RMD
News
- ResMed Inc. (NYSE: RMD) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $205.00 to $200.00. They now have an "outperform" rating on the stock.MarketBeat
- Why ResMed Stock Is Soaring Today [Yahoo! Finance]Yahoo! Finance
- ResMed Inc. (NYSE: RMD) had its price target raised by analysts at Royal Bank of Canada from $187.00 to $200.00. They now have a "sector perform" rating on the stock.MarketBeat
- ResMed (RMD) Q3 Earnings Beat Estimates, Margins Expand [Yahoo! Finance]Yahoo! Finance
- ResMed Inc. (NYSE: RMD) had its price target raised by analysts at KeyCorp from $227.00 to $238.00. They now have an "overweight" rating on the stock.MarketBeat
RMD
Earnings
- 4/25/24 - Beat
RMD
Sec Filings
- 4/29/24 - Form 144
- 4/26/24 - Form 10-Q
- 4/25/24 - Form 8-K
- RMD's page on the SEC website